Peluntamig (PT217)

PreclinicalSmall molecule

Peluntamig (PT217) is one of 55 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaActive, not recruiting

Small Cell Lung Cancer ( SCLC )Recruiting

Neuroendocrine CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

Competition

Competitive Landscape

96 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Tarlatamab-Dznl

Amgen

Phase 3

5 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

1 3

Inlyta

PPrism Pharmaceuticals

Phase 3

1 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

—5

Xpovio

KKaryopharm Therapeutics Inc

Sandostatin LAR

1 7

Keytruda

Merck & Co.

Phase 2

3 8

Afinitor

Novartis

Phase 2

2 9

Taxol

Teva

Phase 2

2 10

Yervoy

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Small Cell Lung Cancer ( SCLC )

NCT05652686

Clinical

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

Recruiting·PPhanes Therapeutics·Preclinical·NCT05652686·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peluntamig (PT217). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peluntamig (PT217) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peluntamig (PT217). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phanes Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPhanes Therapeutics

Peluntamig (PT217)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

References

Drug Info

Quick Facts

Related News